In the treatment of T2DM and DKD with a GFR of 30-60 mL/min/1.73 m2 or albuminuria >200 mg/g, the use of SGLT2 inhibitors is RECOMMENDED to reduce progression to end-stage renal disease and death. This evidence concerns the gene SLC5A2 and chronic kidney disease.